The European Union has approved MAVIRET (glecaprevir/pibrentasvir) for treating acute hepatitis C virus (HCV) infection in adults and children aged 3 and older. This is the only treatment in the EU approved for both acute and chronic HCV, enabling earlier intervention to reduce liver disease progression and transmission. The approval is based on a Phase 3 study showing 96.2% cure rates with an eight-week regimen and a favorable safety profile. AbbVie aims to support broader HCV elimination efforts with this new treatment option.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
